<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02273765</url>
  </required_header>
  <id_info>
    <org_study_id>ANRS 12300 REFLATE TB2</org_study_id>
    <nct_id>NCT02273765</nct_id>
  </id_info>
  <brief_title>Raltegravir Versus Efavirenz in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis</brief_title>
  <acronym>REFLATE TB2</acronym>
  <official_title>Phase III Open-label Randomized Multicenter Trial to Assess the Non-inferiority of Raltegravir Compared With EFavirenz, Both in Combination With LAmivudine and TEnofovir, in ART-naïve HIV-1-infected Patients Receiving Rifampin for Active TuBerculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase III trial evaluating raltegravir as an alternative to efavirenz for antiretroviral
      treatment of HIV-infected patients with tuberculosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase III multicenter, international, open-label, randomized trial evaluating non-inferiority
      of raltegravir at dose of 400mg BID compared to efavirenz 600mg QD, both in association with
      tenofovir disoproxil fumarate and lamivudine in ART-naïve HIV-1 infected patients with active
      TB disease receiving a rifampin-based TB treatment initiated &lt;8 weeks before inclusion.
      Patients will be randomized between 2 arms: the raltegravir (RAL) 400 mg bid arm or the
      efavirenz (EFV) 600 mg qd arm, each in combination with tenofovir disoproxil fumarate (TDF)
      and lamivudine (3TC) and will be followed for 48 weeks after entry in the trial (ART
      initiation).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients in virologic success</measure>
    <time_frame>Week 48</time_frame>
    <description>Virologic success, defined as plasma HIV-1 RNA &lt;50 copies/mL, at week 48 with a window period of 42 to 54 weeks (snapshot algorithm). Discontinuation of the strategy (ie. permanent discontinuation of EFV, RAL), missing values, loss to follow-up and death will be considered as failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to death</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, type and time to new or recurrent AIDS-defining illnesses</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, type and time to severe HIV-associated non-AIDS defining illnesses</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, type and time to grade 3 or 4 adverse events</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, type and time to drug-induced clinical or biological adverse reactions of grade 3 or 4 or leading to treatment interruption</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma HIV-1 RNA from baseline to week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients in virologic success at each time point (HIV-1 RNA&lt;50 copies/mL)</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to virologic failure during follow-up</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and time to new antiretroviral genotypic resistance in plasma RNA in patients with virologic failure</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in CD4 cell counts from baseline to week 48</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency, type and time to Immune Reconstitution Inflammatory Syndrome</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of tuberculosis treatment outcomes</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>HIV-1 Infection</condition>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Raltegravir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tenofovir 300mg QD + lamivudine 300mg QD + raltegravir 400mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Efavirenz</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tenofovir 300mg QD + lamivudine 300mg QD + efavirenz 600mg QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir + lamivudine + raltegravir</intervention_name>
    <description>In this arm, patients will receive the following medications :
Tenofovir disoproxil fumarate (TDF) 300 mg / Lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)
Raltegravir (RAL) 400 mg (Isentress®): twice daily (1 tablet bid), with food
In countries where TDF/3TC FDC is not available, the following separate drugs will be used:
Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)
Lamivudine (3TC) : 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)
Raltegravir (RAL) 400 mg (Insentress®): twice daily (1 tablet bid), with food</description>
    <arm_group_label>Raltegravir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir + lamivudine + efavirenz</intervention_name>
    <description>In this arm, patients will receive the following medications, in accordance with treatment guidelines in all countries:
Tenofovir disoproxil fumarate (TDF) 300 mg / lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)
Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd)
OR:
• Tenofovir disoproxil fumarate (TDF) 245 300 mg / lamivudine (3TC) 300 mg / efavirenz (EFV) 600 mg: once a day (1 tablet qd), at night, if possible without food
In countries where TDF/3TC FDC is not available, the following separate drugs will be used:
Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)
Lamivudine (3TC): 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)
Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd), if possible without food. The dose will not be adapted to the patient's body weight.</description>
    <arm_group_label>Efavirenz</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form

          -  Aged 18 years or more

          -  Confirmed HIV-1 infection as documented at any time prior to trial entry per national
             HIV testing procedures

          -  ART naïve

          -  For women of childbearing potential i.e. women of childbearing age who are not
             menopausal, or permanently sterilized (e.g. tubal occlusion, hysterectomy, bilateral
             salpingectomy) or not refraining from sexual activity: negative urinary test for
             pregnancy and acceptance to use contraceptive methods

          -  Confirmed or probable active TB disease of any location, except neurological
             (meningitis or encephalitis), according to the following criteria based on WHO updated
             definitions:

               -  Bacteriologically confirmed pulmonary TB (PTB) or extrapulmonary TB (EPTB), e.g.
                  TB with a biological specimen positive by smear microscopy, culture or nucleic
                  acid amplification test (such as Xpert MTB/RIF).

               -  Clinically diagnosed PTB or EPTB with typical histological evidence of TB
                  (caseous or granulomatous) on biopsy specimen or positive urinary LAM test OR a
                  significant improvement on TB treatment

          -  Ongoing standard rifampin-containing TB treatment for ≤8 weeks at inclusion

          -  For French patients, affiliation to a Social Security program

        Exclusion Criteria:

          -  HIV-2 co-infection

          -  Impaired hepatic function (icterus or ALT (SGPT) &gt; 5ULN)

          -  Hemoglobin &lt; 6.5 g/dl

          -  Creatinine clearance &lt;60ml/min (assessed by the Cockroft and Gault formula)

          -  Mycobacterium tuberculosis strain resistant to rifampin (current or past history).

          -  Neurological TB (meningitis or encephalitis)

          -  Severe associated diseases requiring specific treatment (including all specific AIDS
             defining illnesses other than TB, and any severe sepsis)

          -  Any condition which might, in the investigator's opinion, compromise the safety of
             treatment and/or patient's adherence to trial procedures including very severe
             TB-related clinical condition

          -  Concomitant treatments including phenytoin or phenobarbital (compounds interacting
             with UGT1A1)

          -  For HCV co-infected patients, need to start specific treatment for hepatitis during
             the trial duration

          -  For women of childbearing potential:

               -  Pregnancy or breastfeeding

               -  Refusal to use a contraceptive method

               -  Any history of ARV intake for prevention of mother to child transmission of HIV
                  (pMTCT)

          -  Subjects participating in another clinical trial evaluating therapies and including an
             exclusion period that is still in force during the screening phase

          -  Person under guardianship, or deprived of freedom by a judicial or administrative
             decision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beatriz Grinsztejn, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Laboratory on Clinical research on DST/AIDS-IPEC FIOCRUZ Av Brasil, 4365 Manguinhos Rio de Janeiro, Brazil CEP 21040-900</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nathalie De Castro, MD</last_name>
    <role>Study Chair</role>
    <affiliation>AP-HP Hôpital Saint-Louis 1 avenue Claude Vellefaux, 75010 Paris, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nathalie De Castro, MD</last_name>
    <phone>+33 142 494 572</phone>
    <email>nathalie.de-castro@sls.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beatriz Grinsztejn, MD, PhD</last_name>
    <phone>+55 21 38 65 95 95</phone>
    <email>beatriz.grinsztejn@ipec.fiocruz.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Laboratory of clinical research on STD/AIDS - IPEC/FIOCRUZ</name>
      <address>
        <city>Rio de Janeiro</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Beatriz Grinsztejzn, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valdilea Veloso, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PACCI / CePReF Centre de Prise en charge de Recherche et de Formation</name>
      <address>
        <city>Abidjan</city>
        <country>Côte D'Ivoire</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eugène Messou, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eholié Serge, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Michel Molina, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie De Castro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Saude / Hospital Geral de Machava</name>
      <address>
        <city>Maputo</city>
        <country>Mozambique</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nilesh Bhatt, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Celso Khosa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pham Ngoc Thach Hospital</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Huu Lân Nguyen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laureillard Didier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
    <country>Côte D'Ivoire</country>
    <country>France</country>
    <country>Mozambique</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2014</study_first_submitted>
  <study_first_submitted_qc>October 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2014</study_first_posted>
  <last_update_submitted>October 4, 2016</last_update_submitted>
  <last_update_submitted_qc>October 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 5, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Efavirenz</mesh_term>
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

